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but rather where list prices are lower than in comparable countries. Objectives: 
The aim of this research is to understand the impact of H2H data on the Service 
Médical Rendu (SMR) and Amélioration du Service Médical Rendu (ASMR) ratings fol-
lowing passage of the law. MethOds: Transparency Commission (TC) reports for new 
drugs or indication expansions of existing drugs published between January 1, 2012 
and March 31, 2013 were reviewed. The following data were gathered: 1) study type 
(placebo-controlled vs active H2H comparator); 2) comparator (if H2H); 3) availability 
of appropriate comparators in the marketplace; and 4) SMR/ASMR ratings. Results: 
A total of 110 TC assessments of 88 drugs were identified and examined. Ninety-four 
of the 110 assessments were of drugs where an appropriate comparator existed in the 
marketplace. Of these 94 assessments, H2H trials were conducted in 54 assessments. 
The percentage of assessments in the H2H group obtaining an SMR of important (78%) 
was similar to those that did not conduct H2H trials (75%). In contrast, the percent-
age of assessments in the H2H group obtaining an ASMR of III or IV was greater than 
the non-H2H group (15% vs. 26%). cOnclusiOns: The conduct of H2H trials does 
not guarantee an SMR of important for new drugs or indication extensions, but may 
improve ASMR rating. Although the TC mentions the lack of comparative data as a 
major contributing factor for an SMR of insufficient in their assessments of some 
products (Daxas, Xiapex), other factors, such as adverse events or efficacy data vs 
placebo are equally important.
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Objectives: To understand how patient-reported outcomes (PROs) influence deci-
sions made by Health Technology Assessment (HTA) agencies. MethOds: Reports 
from five HTA agencies that make reimbursement decisions (NICE, HAS, SMC, PBAC 
and CADTH’s CDR) were selected. The reports, taken from January 2005-April 2013, 
cover disease conditions in neurological and respiratory therapeutic areas. PROs 
within the HTA reports were identified and four analysts independently examined 
the stated rationales for the agencies’ decisions to determine whether PROs had a 
positive, negative, or neutral influence on the decision. Discrepancies between the 
analysts were discussed in-depth until consensus was reached. Results: A total of 
262 HTA reports were analyzed from the five agencies selected. PROs were mentioned 
in 34% of the HTA reports, and were the primary endpoint in 6%. Twenty-five (10%) 
reports mentioned PRO in the clinical rationale for their decisions. Twelve of the 25 
HTA reports (48%) contained PRO as a primary outcome, indicating that a PRO is more 
likely to influence the decision-making process if it is a primary outcome (p < 0.001). In 
12 out of the 25 HTA reports, the clinical rationale for the decision stated that, for the 
PRO, the drug performed better than placebo or comparator. Ten (83%) of these reports 
resulted in a positive decision. In eight reports, the drug compared equivalently or 
unfavorably to placebo or comparator for the PRO and resulted in four (50%) positive 
decisions. There was no significant difference in agency decisions between the reports 
that positively reported PROs and the reports with negative or similar PRO results 
(p= 0.16). cOnclusiOns: In respiratory and neurological diseases, the use of PROs 
is more likely to influence decision-making by HTA agency when PROs are specified 
as primary outcomes. Future research directions include comparing these findings 
to the effect other clinical outcomes have on reimbursement decisions.
PHP164
HealtH economIc (He) data RequIRements and avaIlabIlIty In tHe 
euRoPean unIon. Results of a suRvey
Skoupa J.1, Annemans L.2, Hájek P.3
11st Medical Faculty, Charles University, Prague, Czech Republic, 2Ghent University & Brussels 
University, Ghent, Belgium, 3Pfizer, Praha, Czech Republic
Objectives: To compare data requirements and their availability for HE evaluations 
in 5 countries in Central/Eastern Europe - Poland, Czech Republic, Slovakia, Hungary, 
Romania (CEE) and 5 in Western Europe – UK, France, Germany, The Netherlands, 
Sweden (WE). MethOds: A questionnaire was developed and distributed to market 
access representatives from Pfizer who were asked to complete the questionnaire 
with opinion leader’s support. The questionnaire focused on the obligation to con-
duct HE assessment for reimbursement submissions, local HE guidelines, applied 
discount rates for future costs and effects, willingness to pay (WTP) thresholds 
and available data sources. Results: HE is mandatory in all CEE and 3 WE par-
ticipating countries for reimbursement applications of innovative drugs. Usually 
cost-effectiveness (CEA) and budget-impact (BIA) analyses are required. The pre-
ferred outcome of CEA is quality-adjusted-life years. In Romania, France and Czech 
Republic guidelines could not be identified at the time of the survey. HE evaluations 
are usually prepared by the applicant; in Sweden, UK, The Netherlands and Poland 
unlocked models have to be presented for scrutiny. Discount rates vary from 1.5% 
to 5%; usually the same for costs and outcomes (except in The Netherlands and 
Poland). Only UK, Poland and Slovakia have an explicit WTP threshold. In Poland 
it is based on GDP per capita, in Slovakia on multiples of average monthly wages. 
Differences were found on data availability. In WE data can be acquired easier com-
pared to CEE. Health insurance funds do not provide their data, unless they were 
published. Patient registries are either not available in CEE or difficult to access, so 
applicants mostly rely on retrospective medical chart data, hospital information 
systems or expert panels. cOnclusiOns: We found similar requirements for HE 
analyses in CEE and WE but differences in data availability. This results in less 
accurate inputs across the CEE influencing analyses’ outcomes.
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cedures according to the EUnetHTA Core Model. To avoid any conflict of interests, 
no fee is paid to any member. Results: Since 2011, three HTA reports have been 
completed focusing in 2011-2012 on hepatology (HCV/HBV screening and treat-
ments) and extending in 2013 to other topics including hepatocellular carcinoma 
and inflammatory bowel diseases; HIV is coming up next year. Along with 4 pub-
lications in international journals (mean impact factor 5.73), there have been 
auditions at the Italian Drug Agency (AIFA) and at the Healthcare Commission 
in Parliament that have facilitated the approval of new HCV drugs. Furthermore, 
delays in approvals by regional formularies have been reduced by about 65% 
(from 212 days after national marketing authorization to 74 days; Farmindustria 
data). cOnclusiOns: This new multidisciplinary and multistakeholder approach 
proved to be well-accepted, and the “WEF method” is already recognized as a 
milestone in the Italian HTA landscape, by both Institutions (e.g. AIFA and Italian 
MoH) and Scientific Societies, thus helping payers in making rational decisions 
based on HTA methods.
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Objectives: Health technology assessment (HTA) agencies use an incremental 
cost-effectiveness ratio (ICER) threshold, generally understood to be £30,000 for 
NICE (England), £20,000 for the SMC (Scotland), CAN$50,000 for CADTH (Canada), 
and AUS$42,000 for PBAC (Australia). To help inform future submissions, we 
assessed the rationale provided by the four HTA agencies when submissions 
were accepted despite the reported ICERs being higher than these thresh-
olds. MethOds: All HTA appraisals from January 2000 to May 2013 from NICE, 
SMC, CADTH, and PBAC were included in the analysis. Multiple technology apprais-
als, resubmissions, vaccination programmes, requests for advice, and submissions 
for which an ICER could not be determined were excluded from the analysis. The 
full responses of the remaining appraisals were reviewed, with the submitted 
ICER (with and without proposed PAS), recommendation, and reasoning behind 
the recommendation extracted. Results: A total of 594 submissions met the 
inclusion criteria and 240 included a higher-than-threshold ICER, with 75 (31.6%) 
accepted. The key rationale for acceptance was a lack of alternative treatments 
(25/75). Submissions were also accepted based on the inclusion of a PAS (21/75), a 
demonstrated cost-effectiveness in a restricted patient population (16/75), and a 
robust economic evaluation resulting in a certain ICER (13/75). The agencies con-
sistently based their rationale on clinical need and cost-effectiveness, although 
the proportions varied between the agencies: NICE (53.3%), SMC (59.4%), CADTH 
(70.0%), PBAC (81.8%). cOnclusiOns: The majority of submissions reporting 
ICERs greater than the threshold ICER were rejected. ICERs over the threshold ICER 
were either brought in line with the threshold ICER through PASs or restricting 
the patient population; or accepted in spite of the high ICER based a clear clinical 
need or a robust and certain economic analysis. This highlights the importance 
for manufacturers to provide robust and appropriately justified economic evalu-
ations, even at the expense of an ICER lower than threshold.
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Objectives: To evaluate all medicines that received a conditional regulatory approval 
in Europe and to compare these decisions with the products current market access 
status through the evaluation of Health Technology Assessments (HTAs). MethOds: 
A manual search of the European Medicines Agencies (EMA) website was carried out 
to identify all pharmaceuticals that received a conditional approval (January 2007 to 
May 2013). Of the medicines identified, the statutory funding status was checked by 
reviewing the websites of the key HTA agencies in the EU 5 countries-: HAS (France), 
G-BA (Germany), AIFA (Italy), DGFPS (Spain) and AWMSG, NICE, SMC (UK). Results: 
A total of 15 pharmaceuticals were found that had received an EMA conditional 
approval. Of these, 10 met the inclusion criteria and were analysed further: etra-
virine, everolimus, fampridine, lapatinib, ofatumumab, panitumumab, pixantrone, 
pazopanib, stiripentol and vandetanib. Of the 10 pharmaceuticals, a total of 50 HTA 
assessments were conducted by the 7 agencies, with 31 (62%) of the HTAs reaching a 
positive funding decision. Both NICE and AWMSG recommended only 1 of the condi-
tionally approved drugs for funding, G-BA recommended 2, SMC 3, DGFPS 6, AIFA 6 and 
HAS 8. Of the 10 drugs, everolimus was the most successful and is funded by 6 (of the 
7) HTA agencies. The key reasons for the success of everolimus were due to convincing 
efficacy (prolonging progression-free survival), combined with an economic case that 
was considered demonstrated despite some uncertainties. cOnclusiOns: Whilst 
regulatory bodies recognise the need to grant marketing authorisation on the basis 
of less complete data, this does not necessarily mean a straight forward path through 
market access. Although the majority of HTA agencies did provide a positive funding 
decision; sound health economic evidence remains essential for new medicines to 
increase the chances of market access approval.
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bAckgROund: Since December 2011, pharmaceutical companies are required by 
law to provide the Haute Autorité de Santé with head-to-head (H2H) data against 
standard of care when available to be entitled for reimbursement. However, France 
is a market where health authorities rarely deny reimbursement to innovative drugs 
